Previous Page
11-10 :: October 2011
nanotimes
Companies Facts
construction of a single-span bridge in Northern Ire- land or its flexible connectors for the Passive House in England, an innovative project. By the way, the strict requirement the British had for fire resistance of materials prompted the company’s engineers to begin experiments with nanomodifiers for polymer connectors,” noted RUSNANO Managing Director Alexander Kondrashov.
The composite materials that Galen manufactures contain basalt fiber produced using pultrusion, a continuous molding process, with an epoxy binder that is resistant to halogens, acids, and alkalis. The disadvantage of the composite’s relatively low com- bustion temperature has been overcome by adding to the epoxy binder a small amount of nanoparticles of aluminosilicate montmorillonite based largely on clay. This also improves the strength of the composite under flexion.
Moreover, RUSNANO is co-investing $25 million in BIND and $25 million in Selecta, for a total RUS- NANO investment of $50 million within the total financing rounds of $94.5 million in the two com- panies combined. The remaining co-investments, $22.25 million in each company, come from current and new investors of BIND and Selecta. BIND Biosci- ences and Selecta Biosciences are two nanomedicine companies. BIND develops targeted therapeutics, called Accurins™, that selectively accumulate at the site of disease to dramatically enhance effectiveness for treating cancer and other diseases. BIND’s lead candidate, BIND-014, is in human clinical trials as a targeted therapy for cancer treatment. BIND’s de- velopment pipeline also includes a range of cancer treatments and drugs for anti-inflammatory and car- diovascular conditions.
Selecta Biosciences, Inc. is developing a new class of targeted vaccines, synthetically engineered and capable of inducing targeted antigen-specific immu- ne responses to prevent and treat diseases. Selecta‘s proprietary Synthetic Vaccine Particle (SVP™) plat- form is the bases for two product lines, targeted Synthetic Vaccine Particles (tSVP™) and targeted tolerogenic Synthetic Vaccine Particles (t2SVP™).
http://www.bindbio.com http://www.selectabio.com http://www.rusnano.com
31
S
amsung Electronics Co., Ltd., and Cadence Design Systems, Inc. (NASDAQ:CDNS), an-
nounced the initial production of Ambarella’s 32nm HD digital camera system-on-chip (SoC). This SoC, in production at the S1-Line at Samsung’s Giheung facility, was built using 32nm gate-first High-k Me- tal Gate (HKMG) process technology from Samsung Electronics’ foundry business, Samsung Foundry, a complete Cadence digital design flow including the Encounter and Incisive platforms and ARM Cortex™ processor and Artisan®
physical IP. Leveraging
the combined technology leadership of Samsung Foundry and Cadence, the new Ambarella A7L SoC brings new levels of performance and power savings to digital lifestyle HD camera applications.
iluria Technologies received $20 million in funding to commercialize its process for conver- ting methane into fuel and chemicals. The Series B